649736-26-5

Usage

Uses

Used in Pharmaceutical Research:
6-(Benzyloxy)-5-Methylpyrimidine is used as a key intermediate in the synthesis of various heterocyclic compounds with diverse biological and pharmaceutical functions. Its unique structure allows for the development of new drugs and medications.
Used in Drug Discovery:
6-(Benzyloxy)-5-Methylpyr... is utilized as a building block in drug discovery, contributing to the creation of potential antiviral and anticancer agents. Its pharmacological properties are being studied to explore its therapeutic potential in treating various diseases.
Used in Organic Synthesis:
6-(Benzyloxy)-5-Methylpyrimidine serves as a valuable component in organic synthesis, enabling the production of a wide range of chemical compounds with different applications across various industries.

Upstream product

• 64-17-5 ethanol 
• 100-39-0 benzyl bromide 
• 886585-68-8 6-(benzyloxy)-5-methyl-4-phenoxypyrrolo[2,1-f][1,2,4]triazine 
• 310444-84-9 4-Phenoxy-5-methyl-6-hydroxypyrrolo[2,1-f][1,2,4]triazine 

Downstream Products

• 649735-41-1 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol 
• 649735-46-6 Brivanib 
• 649736-28-7 6-(benzyloxy)-4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine 
• 649736-27-6 6-(benzyloxy)-4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine 

Relevant academic research and scientific papers

Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol- 5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor

A series of substituted 4-(4-fluoro-1H-indol-5-yloxy)pyrrolo-[2.1-f][1,2,4] triazine-based inhibitors of vascular endothelial growth factor receptor-2 kinase is reported. Structure-activity relationship studies revealed that a methyl group at the 5-position and a substituted alkoxy group at the 6-position of the pyrrolo[2,1-f][1,2,4]triazine core gave potent compounds. Biochemical potency, kinase selectivity, and pharmacokinetics of the series were optimized and in vitro safety liabilities were minimized to afford BMS-540215 (12), which demonstrated robust preclinical in vivo activity in human tumor xenograft models. The L-alanine prodrug of 12, BMS-582664 (21), is currently under evaluation in clinical trials for the treatment of solid tumors.

PROCESS FOR PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS

The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.